Biotech Catalysts This Week: FDA Decisions, Readouts & Earnings (Aug 9–Aug 16, 2026)
Here’s what’s on the biotech calendar for August 9–August 16: 0 FDA decision dates, 3 trial catalysts, and 13 earnings reports from tracked companies.
🧪 Trial Catalysts & Milestones
- ACRV, 2026-08-12: Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors
📊 Earnings This Week
- SLS, 2026-08-10 (est. EPS -0.05)
- SPRO, 2026-08-10 (est. EPS -0.17)
- ADCT, 2026-08-10 (est. EPS -0.21)
- MAIA, 2026-08-10 (est. EPS -0.11)
- ORIC, 2026-08-10 (est. EPS -0.37)
- APGE, 2026-08-10 (est. EPS -1.09)
- BHVN, 2026-08-10 (est. EPS -0.74)
- VERU, 2026-08-10 (est. EPS -0.33)
- AIM, 2026-08-12 (est. EPS -0.17)
- CADL, 2026-08-12 (est. EPS -0.24)
- IBRX, 2026-08-12 (est. EPS -0.09)
- SPRO, 2026-08-12 (est. EPS -0.17)
- OSTX, 2026-08-13 (est. EPS -0.21)
📡 Run-up Radar Highlights
Stocks entering the pre-catalyst window with the strongest setups (full radar is a Premium feature):
- CAPR: BLA in 13 days, score 73/100
- ZYME: NDA in 16 days, score 48/100
- JAZZ: sBLA in 16 days, score 48/100
📈 Last Week’s Biggest Gainers
- BRVE +65.56% (volume 0.0x average)
- IOVA +43.09% (volume 4.9x average)
- INSM +33.86% (volume 3.1x average)
Track your tickers on the BioRadar dashboard →
This digest is for informational purposes only and is not investment advice. Always do your own research.